Detalles de la búsqueda
1.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589856
2.
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Int J Cancer
; 151(8): 1310-1320, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35723131
3.
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 563, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38711003
4.
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
JAMA Netw Open
; 7(1): e2350756, 2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38190183
5.
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).
Ther Adv Med Oncol
; 16: 17588359231217958, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38264520
6.
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
Target Oncol
; 19(2): 223-235, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38345693
7.
Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?
Cancers (Basel)
; 15(17)2023 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37686493
8.
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Tumori
; 109(1): 129-137, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36447337
9.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Clin Lung Cancer
; 24(7): 631-640.e2, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775370
10.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
J Hematol Oncol
; 16(1): 119, 2023 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098114
11.
Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy.
Cancer Manag Res
; 14: 3071-3081, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36275783
12.
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.
JCO Precis Oncol
; 6: e2200037, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35544729
13.
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index.
J Gastrointest Cancer
; 53(3): 528-536, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34033000
14.
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers.
Mol Oncol
; 16(14): 2733-2746, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35621918
15.
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.
Front Oncol
; 12: 1078822, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36755856
16.
Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma.
Cancers (Basel)
; 13(15)2021 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34359706
17.
Multidrug regimens for treatment of older patients with metastatic pancreatic cancer.
Dig Liver Dis
; 53(1): 117-121, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32631650
18.
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Cancers (Basel)
; 13(6)2021 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33803958
19.
COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study.
ESMO Open
; 5(Suppl 3)2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33158968
20.
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Lancet Gastroenterol Hepatol
; 3(10): 691-697, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30220407